Details of Drug-Drug Interaction
| Drug General Information (ID: DDI4CGOSMA) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Drug Name | Conjugated estrogens (topical) | Drug Info | Budesonide | Drug Info | |||||
| Drug Type | Small molecule | Small molecule | |||||||
| Therapeutic Class | Estrogens | Antiinflammatory Agents | |||||||
| Structure | |||||||||
| Mechanism of Conjugated estrogens (topical)-Budesonide Interaction (Severity Level: Moderate) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Increase globulin concentration Click to Show/Hide Mechanism Graph | |||||||||
 |
|||||||||
| Drug Name | Conjugated estrogens (topical) | Budesonide | |||||||
| Mechanism | Increase serum cortisol-binding globulin concentration | Corticosteroid | |||||||
| Key Mechanism Factor 1 | |||||||||
| Factor Name | Pharmacokinetics | ||||||||
| Factor Description | Alters the distribution of the drug, leading to changes in the plasma concentration of the drug and affecting the pharmacological effects. | ||||||||
| Mechanism Description |
|
||||||||
| Recommended Action | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Management | Patients treated concomitantly with an estrogen-containing drug may require lower dosages of corticosteroids or adrenocorticotropic agents. Pharmacologic response to these agents should be monitored more closely whenever an estrogen is added to or withdrawn from therapy in patients stabilized on their existing corticosteroid or adrenocorticotropic regimen, and the dosage(s) adjusted as necessary. | ||||||||